Sensorion

111 articles with Sensorion

• Sensorion appoints pharmaceutical industry veteran Scott D. Myers as Chairman of the Board and Independent Director

  12/20/2021

  Sensorion, a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, announces the appointment of Scott D. Myers as Chairman of its Board of Directors and Independent Director.

• Sensorion to present in person at “Jefferies London Healthcare Conference”

  11/9/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that Nawal Ouzren, CEO of Sensorion, will participate physically in one investor conference in London.

• Sensorion Surpasses Enrollment Target for SENS-401 in SSNHL, Results Available in January 2022

  10/27/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces 115 patients have been enrolled for treatment in the company’s AUDIBLE-S study of the company’s first-in-class small molecule drug SENS-401 in patients with sudden sensorineural hearing loss.

• Sensorion to Present at “Jefferies Gene Therapy / Editing Summit”

  10/22/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of members of the company’s senior management team at an investor conference.

• Sensorion Hosting Key Opinion Leader Webinar with Dr Nicole C. Schmitt on Cisplatin-Induced Ototoxicity on October 28, 2021

  10/7/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it will host a key opinion leader webinar on cisplatin-induced ototoxicity on Thursday, October 28, 2021 at 10:00am EST/4:00pm CET.

• Sensorion to Attend Three Conferences in October 2021, Including the Cell & Gene Meeting on the Mesa

  9/30/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announce the participation of members of the company’s senior management in three investor and scientific conferences during October 2021.

• Sensorion Reports 2021 First Half Results

  9/27/2021

  Sensorion, a pioneering clinical-stage and gene therapy biotech company specializing in the development of novel therapies to restore, treat, and prevent within the field of hearing disorders, announces its interim annual results as of June 30, 2021 alongside its outlook for the remainder of 2021.

• Regulators Approve Sensorion’s Amendment to Phase 2 AUDIBLE-S Trial of SENS-401 in Sudden Sensorineural Hearing Loss

  9/24/2021

  Sensorion a pioneering clinical-stage biotechnology company specialising in the development of novel therapies to restore, treat and prevent hearing disorders, announces that regulatory authorities of 9 out of 10 participating countries have approved Sensorion’s amendment to the Phase 2 AUDIBLE-S study protocol with SENS-401 in Sudden Sensorineural Hearing Loss.

• 

  Global Roundup: TreeFrog Scores $75 Million, Establishes US Toehold

  9/16/2021

  Biopharma and life sciences companies and organizations from across the globe provide updates on their businesses and pipelines.

• Sensorion And Hearing Care Leader Sonova Sign Strategic Research Collaboration

  9/15/2021

  Sensorion and Sonova, have signed a multi-year strategic collaboration with the aim of introducing genetic analysis to the routine diagnosis of progressive hearing loss in adults, thereby opening the way for improved care through a combination of advanced therapeutic interventions and traditional hearing aids.

• Sensorion and Cochlear to Begin First Clinical Trial of SENS-401 for Hearing Preservation in Combination With Cochlear Implantation

  9/8/2021

  Sensorion a pioneering clinical-stage biotechnology, which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, and Cochlear Limited, the global leader in implantable hearing solutions, announce the initiation of a pilot study of the first-in-class small molecule drug SENS-401 in patients scheduled for cochlear implantation.

• Sensorion Appoints Ex-Novartis Cell Therapy & Viral Vectors Head Otmane Boussif as Chief Technical Officer

  7/20/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the appointment of Otmane Boussif, a senior leader with extensive experience in managing global Chemistry, Manufacturing and Controls organizations, as Chief Technical Officer, effective August 1, 2021.

• Sensorion Appoints Gene Therapy and Rare Disease Expert Nora Yang as Chief Scientific Officer

  6/10/2021

  Sensorion announces the appointment of Nora Yang, Ph.D., a leader in gene therapy and rare diseases with extensive leadership experience in industry, academia, and government, as Chief Scientific Officer.

• Sensorion to Attend Two Conferences in June 2021

  5/27/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of members of the company’s senior management team in two investor conferences being held virtually during June 2021.

• Sensorion Publishes Results of Combined General Meeting Resolutions

  5/18/2021

  Regulatory News: Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces the results of resolutions presented at its Combined General Meeting (CGM) on May 18, 2021and made them available on the dedicated section of its website.

• Sensorion to Attend Three Conferences in May 2021 Including ASGCT to Present a Poster and Co-Chair a Scientific Session

  5/4/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of members of the company’s senior management team in three R&D and investor conferences being held virtually during May 2021.

• Sensorion Hosting Key Opinion Leader Webinar with Dr. Thomas Lenarz on the GJB2 Gene Related Hearing Loss on May 10, 2021

  4/30/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announced that it will host a key opinion leader webinar on GJB2-Related Genetic Hearing Loss on Monday, May 10, 2021 at 10am Eastern Time.

• Sensorion Announces That a General Meeting of Shareholders Will Be Held Behind Closed Doors on May 18, 2021 Alongside the Publication of Its 2020 Annual Financial Report

  4/9/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces that the company's Board of Directors has approved the procedure for holding a Combined General Meeting behind closed doors on Tuesday, May 18, 2021.

• Sensorion Senior Management to Attend Four Conferences in April 2021

  3/31/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the participation of members of the company’s senior management team in four investor and R&D conferences being held virtually during April 2021.

• Sensorion Publishes Results of Extraordinary General Meeting Resolutions

  3/25/2021

  Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the results of resolutions presented at its Extraordinary General Meeting on March 24, 2021 and made them available on the dedicated section of its website.